Drug Allergy Market Is Expected To Reach USD 38.29 Billion By 2032

Pune, India, August 10, 2017 /MRFR Press Release/- Market Research Future has a half cooked research report on the global drug allergy market. The global drug allergy market is growing continuously and expected to grow at a CAGR of 12.20% from 2024 to 2032

Market Highlights

The global drug allergy market is growing moderately and it is expected to grow with the same pace over the forecast period 2024-2032. Increasing prevalence of drug allergies and funding for research & development of the new drugs drive the global market.

The global market of drug allergy was around USD 17.48 Billion in 2023 and is expected to reach USD 38.29 Billion by 2032 at a projected CAGR of 12.20%.

Taste the market data and market information presented through more than 56 market data tables and figures spread over 84 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Drug allergy Market Research Report–Global Forecast to 2024.”

Major Players in Drug Allergy Market

Some of the key market players: AstraZeneca (UK), Bayer (US), Circassia (US), HAL Allergy Group (the Netherlands) Johnson & Johnson Services, Inc. (US), MAGNA Pharmaceuticals, Inc. (US), Stallergenes Greer (UK) and others.

Drug Allergy Market Regional Analysis

The global drug allergy market is consist of four regions: America, Europe, Asia Pacific, and the Middle East & Africa.

Increasing funding for R&D, and ongoing clinical trials of various drugs are driving the growth for the America drug allergy market. The Americas market is consist of North America and Latin America. The drug allergy is one of the most common types of allergy in North America, especially, in the US. The Latin American market holds the least market share; however, this market is expected to grow significantly during the forecast period 2017-2023.

Europe drug allergy market is the second largest market in the globe and growing significantly. According to European Academy of Allergy and Clinical Immunology (EAACI), around 2.6% hospitalization happens due to adverse drug effects while the prevalence of drug allergy in the hospitalized patients is around 10% in the Europe.

Growing awareness about various drug allergies, improving drug standards, and changing healthcare practices are leading the growth of the market in Asia Pacific.

The Middle East & Africa has one of the highest prevalence rate of different allergies, however, lack of awareness about drug allergies, their causes, symptoms, and t available treatments slow down the growth of the market in this region.

Segmentation

The global drug allergy market is segmented on the basis of type, which comprises of immunologic, non-immunologic, and others. Immunologic is sub-segmented into type I reaction, type II reaction, type III reaction, type IV reaction, and others. Non-immunologic allergy is further sub-segmented into predictable, unpredictable, and others. Predictable is sub-segmented into pharmacologic side effect, secondary pharmacologic side effect, drug toxicity, drug-drug interactions, drug overdose, and others. Unpredictable segment is further segmented into pseudoallergic, idiosyncratic, intolerance, and others.

On the basis of diagnosis, the market is segmented into skin tests, blood tests, patch test, and others. Skin test is further segmented into prick or scratch test, intradermal test, and others.

On the basis of treatments, the market has been segmented into antihistamines, corticosteroids, treatment of anaphylaxis, withdrawal of the drug, and others. Antihistamines is further sub-segmented into azelastine eyedrops, azelastine nasal sprays,  carbinoxamine , cyproheptadine, desloratadine, diphenhydramine, emedastine eyedrops, hydroxyzine, levocabastine eyedrops, levocabastine oral, and others. Corticosteroids is sub-segmented into topical steroids, inhaled steroids, and others. Inhaled steroids is further segmented into flunisolide, fluticasone furoate, fluticasone propionate, triamcinolone acetonide, beclomethasone dipropionate, budesonide, and others.

On the basis of end user, it is segmented into hospital & clinics, medical research centers, academic institutes, and others.